Literature DB >> 10945607

Novel transcripts of fibroblast growth factor receptor 3 reveal aberrant splicing and activation of cryptic splice sequences in colorectal cancer.

J H Jang1, K H Shin, Y J Park, R J Lee, W L McKeehan, J G Park.   

Abstract

A nested reverse transcription-PCR analysis of FGFR3 from human colorectal carcinomas revealed novel mutant transcripts caused by aberrant splicing and activation of cryptic splice sequences. Two aberrantly spliced transcripts were detected with high frequency in 50% of 36 primary tumors and in 60% of 10 human colorectal cancer cell lines. Most transcripts used normal splice sites but skipped or included exons 8 and 9. Two mutant transcripts arose from cryptic splice donor sites in exon 7 that spliced to exon 10. The predicted translation products would exhibit frameshifts and a premature termination codon in exon 10. We propose that dysregulation of mRNA splicing frequently generates an aberrant FGFR3 transcript that may confer a selectable advantage on clones of cells in colorectal tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10945607

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  FGF9/FGFR2 increase cell proliferation by activating ERK1/2, Rb/E2F1, and cell cycle pathways in mouse Leydig tumor cells.

Authors:  Ming-Min Chang; Meng-Shao Lai; Siou-Ying Hong; Bo-Syong Pan; Hsin Huang; Shang-Hsun Yang; Chia-Ching Wu; H Sunny Sun; Jih-Ing Chuang; Chia-Yih Wang; Bu-Miin Huang
Journal:  Cancer Sci       Date:  2018-10-23       Impact factor: 6.716

Review 2.  Signaling from novel splice variants of hormone receptors in cancer.

Authors:  Wei-Qun Ding; Laurence J Miller
Journal:  Int J Gastrointest Cancer       Date:  2002

3.  Over-expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma.

Authors:  Wei-Hua Qiu; Bing-Sen Zhou; Peiguo-G Chu; Wen-Gang Chen; Christopher Chung; Jennifer Shih; Paul Hwu; Christopher Yeh; Richard Lopez; Yun Yen
Journal:  World J Gastroenterol       Date:  2005-09-14       Impact factor: 5.742

4.  Biology of SNU cell lines.

Authors:  Ja-Lok Ku; Jae-Gahb Park
Journal:  Cancer Res Treat       Date:  2005-02-28       Impact factor: 4.679

5.  Fibroblast growth factor receptor 3-IIIc mediates colorectal cancer growth and migration.

Authors:  G Sonvilla; S Allerstorfer; C Heinzle; S Stättner; J Karner; M Klimpfinger; F Wrba; H Fischer; C Gauglhofer; S Spiegl-Kreinecker; B Grasl-Kraupp; K Holzmann; M Grusch; W Berger; B Marian
Journal:  Br J Cancer       Date:  2010-03-16       Impact factor: 7.640

6.  Resident hepatocyte fibroblast growth factor receptor 4 limits hepatocarcinogenesis.

Authors:  Xinqiang Huang; Chaofeng Yang; Chengliu Jin; Yongde Luo; Fen Wang; Wallace L McKeehan
Journal:  Mol Carcinog       Date:  2009-06       Impact factor: 4.784

7.  Fibroblast growth factor receptor 2: expression, roles, and potential as a novel molecular target for colorectal cancer.

Authors:  Yoko Matsuda; Junji Ueda; Toshiyuki Ishiwata
Journal:  Patholog Res Int       Date:  2012-06-04

8.  Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models.

Authors:  Dorothy M French; Benjamin C Lin; Manping Wang; Camellia Adams; Theresa Shek; Kathy Hötzel; Brad Bolon; Ronald Ferrando; Craig Blackmore; Kurt Schroeder; Luis A Rodriguez; Maria Hristopoulos; Rayna Venook; Avi Ashkenazi; Luc R Desnoyers
Journal:  PLoS One       Date:  2012-05-15       Impact factor: 3.240

9.  Alternative Splicing of Fibroblast Growth Factor Receptor IgIII Loops in Cancer.

Authors:  Klaus Holzmann; Thomas Grunt; Christine Heinzle; Sandra Sampl; Heinrich Steinhoff; Nicole Reichmann; Miriam Kleiter; Marlene Hauck; Brigitte Marian
Journal:  J Nucleic Acids       Date:  2011-12-12

10.  FGFR3IIIS: a novel soluble FGFR3 spliced variant that modulates growth is frequently expressed in tumour cells.

Authors:  L-M Sturla; A E Merrick; S A Burchill
Journal:  Br J Cancer       Date:  2003-10-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.